Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Tumour evolution

Mutable markers

Nature Reviews Cancer volume 12, page 511 (2012)Cite this article

Subjects

Access through your institution
Buy or subscribe

Lindström et al. scored hundreds of breast cancer relapse samples for oestrogen receptor (ER), progesterone receptor (PR) and ERRB2 (also known as HER2) status. They compared these scores with the status of each protein recorded at diagnosis and found status changes for ER and PR in one-third of cases, and for ERBB2 in 15% of cases, with some of these correlating with poor survival. Thus, repeat biopsies would be useful to optimize treatment decisions.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Lindström, L. S. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J. Clin. Oncol. 2 Jul 2012 (doi:10.1200/JCO.2011.37.2482)

Download references

Authors
  1. Darren J. Burgess
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burgess, D. Mutable markers. Nat Rev Cancer 12, 511 (2012). https://doi.org/10.1038/nrc3338

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrc3338

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer